Dupuytren's contracture treatment

This is a summary of the NEW Devon CCG commissioning policy for Dupuytren's contracture treatment

Referral

Referral Criteria

Medical treatment for Dupuytren's contracture with collagenase clostridium histolyticum (Xiapex®) is commissioned in accordance with National Institute for Health and Care Excellence (NICE) Technology Appraisal guidance 459.

Surgical treatment for Dupuytren's contracture will be routinely commissioned in Devon in the following circumstances:

  • Metacarpophalangeal joint contracture of 30 degrees or more (inability to put hand flat on table)

Or

  • Any degree of proximal interphalangeal joint contracture

Or

  • Significant functional impairment

Or

  • Where there is significant threat to hand function due to Duputren's diathesis

Significant functional impairment is defined as a loss or absence of an individual's capacity to meet personal, social or occupational demands.

Where the circumstances of treatment for an individual patient do not meet the criteria described above exceptional funding can be sought. Individual cases will be reviewed by the appropriate panel of the CCG upon receipt of a completed application from the patient's GP, consultant or clinician. Applications cannot be considered from patients personally.

Dupuytren's contracture treatment commissioning policy

Exceptional /Individual Funding Requests (IFR)

Supporting Information

Patient Information

Individual Funding Request (IFR) Patient information leaflet

Publication date: Updated September 2017

 

Home > Referral > Policies > Dupuytren's contracture treatment

 

  • First line
  • Second line
  • Specialist
  • Hospital